Chemotherapy-free combination improves survival in metastatic colorectal cancer
(MedPage Today) – Berlin – The investigational tyrosine kinase inhibitor (TKI) zanzalintinib plus atezolizumab (Tecentriq) improved overall survival (OS) among previously treated patients with metastatic colorectal cancer, a stage…